• —

What if radiation therapy could be as precise as a sniper, targeting only cancer cells and leaving healthy ones unscathed?

For decades, radiation has been both a hero and a villain in the world of oncology. Its ability to obliterate cancer cells is unparalleled, yet its lack of precision often leads to collateral damage, impacting patients’ quality of life. However, a groundbreaking advancement from the minds at UC San Francisco is poised to change that narrative. Imagine a world where radiation therapy is not only effective but also extraordinarily precise—a world we might very well be stepping into.

How did scientists transform a cancer-causing protein into a beacon for destruction?

The journey began over a decade ago with the tenacious efforts of UCSF’s Kevan Shokat, PhD, who cracked the code to target KRAS—a notorious oncogene implicated in nearly a third of all cancers. This breakthrough led to the development of drugs that relentlessly clung to KRAS, acting like a molecular spotlight on cancer cells. Although these drugs initially showed promise, the tumors developed resistance, rendering the treatment less effective over time.

Charly Craik, PhD, saw potential in transforming this limitation into an advantage. “We suspected early on that the KRAS drugs might serve as permanent flags for cancer cells,” Craik explained. By 2022, Craik and his team had confirmed that these drugs indeed made cancer cells more detectable to the immune system, a hopeful discovery that needed further refinement.

What role does atomic-level radiation play in this innovative approach?

The answer lay in a collaboration with Mike Evans, PhD, a radiology professor, to supercharge the existing approach. By coupling the KRAS-targeting drugs with antibodies armed with radioactive payloads, they developed a technique that could deliver radiation directly to cancerous cells with surgical precision. This novel method not only eradicated lung cancer in mice but did so with minimal side effects—a stark contrast to traditional radiation therapy. “Radiation is ruthlessly efficient in its ability to ablate cancer cells, and with this approach, we’ve shown that we can direct it exclusively to those cancers,” Evans stated.

How can this therapy be adapted for widespread use among diverse patients?

While the results are promising, the challenge now lies in tailoring this therapy to accommodate the diverse genetic make-up of patients. The current task is to engineer antibodies that recognize the varied presentations of KRAS across different individuals. UCSF’s Kliment Verba, PhD, is utilizing cryo-electron microscopy to visualize these interactions at an atomic scale, offering a blueprint for developing even more effective antibodies. This visualization, affectionately termed the ‘radiation sandwich,’ highlights the potential for creating bespoke treatment strategies.

“We’ve taken a significant step toward patient-specific radiation therapies, which could lead to a new paradigm for treatment,” Verba remarked, underscoring the potential this holds for personalized medicine.

What does the future hold for this pioneering cancer treatment?

The implications of this research extend beyond just lung and bladder cancer. The ability to selectively target cancer cells with minimal harm to the patient is a tantalizing prospect that could revolutionize cancer treatment protocols worldwide. As the UCSF team continues to refine their methods and expand their understanding, the dream of a world where cancer can be treated effectively and gently comes closer to reality.

With continued support from institutions like the NIH and the Howard Hughes Medical Institute, alongside backing from UCSF’s innovation programs, this innovative therapy could soon transition from the lab to the clinic, offering hope and healing to countless patients.

In this brave new world, radiation therapy won’t just be about destruction—it’s about precision, hope, and a clear path forward in the battle against cancer.